L
Larimar Therapeutics, Inc. (LRMR)
NGM – Real vaqt narxi. Valyuta: USD
3.66
+0.16 (4.57%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.00
+0.34 (9.29%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.66
+0.16 (4.57%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.00
+0.34 (9.29%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Larimar Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, o'zining yangi hujayraga singib ketuvchi peptid texnologiyasi platformasidan foydalangan holda kam uchraydigan kasalliklarni davolashni ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi CTI-1601 bo'lib, u Friedreich ataksiyasi, kam uchraydigan, progressiv va o'limga olib keladigan kasallikni davolash uchun 2-bosqich OLE klinik sinovidan o'tmoqda. Kompaniya Bala Cynwyd, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
| Mr. Francis Michael Conway CPA | VP & Controller |
| Mr. John Berman | Vice President of Finance & Administration |
| Mr. Michael Celano CPA | Secretary & CFO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-19 | 8-K | lrmr-20260519.htm |
| 2026-05-14 | 8-K | lrmr-20260514.htm |
| 2026-05-14 | 10-Q | lrmr-20260331.htm |
| 2026-04-20 | DEF 14A | lrmr-20260416.htm |
| 2026-04-20 | ARS | lrmr_ars_123125.pdf |
| 2026-04-10 | PRE 14A | lrmr-20260410.htm |
| 2026-03-19 | S-8 | d122362ds8.htm |
| 2026-03-19 | 8-K | lrmr-20260319.htm |
| 2026-03-19 | 10-K | lrmr-20251231.htm |
| 2026-03-09 | 8-K | lrmr-20260309.htm |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance |